SIAPS Program employs systems-strengthening interventions and specialized tools to promote TB prevention, treatment, and management. Read more about our successes in fighting TB:
In 2012, bedaquiline was conditionally approved by U.S. Food and Drug Administration for the treatment of drug-resistant tuberculosis (TB), making it the first new TB drug to enter the market in more than 40 years. With the rise of multidrug-resistant and extensively drug-resistant TB leaving patients with fewer treatment options, the approval of bedaquiline gave new hope to health professionals and TB sufferers around the world. SIAPS Program provided technical assistance to prepare Swaziland for participation in the donation program–and in doing so learned many valuable lessons.
Pharmaceutical Management for Tuberculosis
SIAPS Program provides technical leadership in pharmaceutical management for global tuberculosis (TB) initiatives, donors, and national TB programs. SIAPS targets result areas that are vital for stronger health systems, such as improved governance, increased capacity for pharmaceutical management, and information for decision making. By implementing activities addressing rational drug use, supply planning, and public-private partnerships, SIAPS helps meet the challenges of TB medicines management.
The first new TB medicines in over 40 years—bedaquiline and delamanid—were recently released onto the market for the treatment of multidrug-resistant tuberculosis (MDR-TB). Since then, these medicines have been used for the treatment of MDR-TB patients as well as TB patients who have experienced life-altering side effects or developed intolerance or resistance to some second-line TB drugs. On this website, you will find general information and guidance documents about bedaquiline (Sirturo™) and delamanid (Deltyba™) from globally recognized bodies such as the World Health Organization.
The PharmacoVigilance Monitoring System (PViMS) is a web-based application used by clinicians, regulatory bodies, and implementing partners to monitor the safety of medicines. PViMS enables the implementation of active surveillance activities in low- and middle-income countries (LMICs) by addressing the entire data collection, data analysis and reporting process. This allows decision makers to identify potential adverse events related to medicine use, and consequently implement decisions for improving patient safety. This will be particularly important as new TB drugs come into wider use.